







Longevity is becoming increasingly popular to elongate health-span. We turn to estrogen to understand its impact on women's long-term well-being.
The Shape-Shifting Power of Menopause
“I know there is a way to grow older that brings us deeply into living.”

When Women Initiate Estrogen Therapy Matters | The Menopause Society
New large-scale analysis shows potential long-term benefits of initiating hormones during perimenopause

The Quest for Longevity Is Already Over
Studying people who live well beyond the age of 100 could reveal the secret to living longer, healthier lives. But the statistics tell another story.

The human ovary exhibits dynamic molecular remodeling in the decades post-menopause
The human ovary is among the first organs to show age-related functional decline, resulting in menopause. Beyond this transition, the postmenopausal ovary is often regarded as quiescent and remains poorly characterized.
Why the Fear Around Hormone Therapy Won’t Die
Effective care in menopause starts with three fundamentals:

Estrogens and Androgens in Skeletal Physiology and Pathophysiology
Estrogens and androgens influence the growth and maintenance of the mammalian skeleton and are responsible for its sexual dimorphism. Estrogen deficiency at menopause or loss of both estrogens and androgens in elderly men contribute to the development of osteoporosis, one of the most common and impactful metabolic diseases of old age. In the last 20 years, basic and clinical research advances, genetic insights from humans and rodents, and newer imaging technologies have changed considerably the landscape of our understanding of bone biology as well as the relationship between sex steroids and the physiology and pathophysiology of bone metabolism. Together with the appreciation of the side effects of estrogen-related therapies on breast cancer and cardiovascular diseases, these advances have also drastically altered the treatment of osteoporosis. In this article, we provide a comprehensive review of the molecular and cellular mechanisms of action of estrogens and androgens on bone, their influences on skeletal homeostasis during growth and adulthood, the pathogenetic mechanisms of the adverse effects of their deficiency on the female and male skeleton, as well as the role of natural and synthetic estrogenic or androgenic compounds in the pharmacotherapy of osteoporosis. We highlight latest advances on the crosstalk between hormonal and mechanical signals, the relevance of the antioxidant properties of estrogens and androgens, the difference of their cellular targets in different bone envelopes, the role of estrogen deficiency in male osteoporosis, and the contribution of estrogen or androgen deficiency to the monomorphic effects of aging on skeletal involution.

Anti-Aging Breakthrough: Detoxing Body of Harmful Fat By-Products To Extend Lifespan
Scientists from the University of Virginia (UVA) have identified a promising approach to delay aging by detoxifying the body of glycerol and glyceraldehyde, harmful by-products of fat that naturally accumulate over time.

Scientists find humans age dramatically in two bursts – at 44, then 60
US findings suggesting ageing is not a slow and steady process could explain spikes in health issues at certain ages

Microdosing Estrogen
Learn about microdosing estrogen regimens and their effects from a quick guide to feminizing hormone therapy.

Four Red Flags and One Truth Amid the Peptide Hype - KFF Health News
Experimental peptides are all the rage on longevity and “optimization” podcasts, but a lot of the chatter is misleading.

Menopausal hormone therapy and coronary heart disease: the roller-coaster history
In the USA it is estimated that more than one million women become menopausal each year. Coronary heart disease (CHD) is the leading cause of mortality in menopausal woman globally. The majority of...

The Strength Training Habits That Slow Aging, According to Science
Exercise is so beneficial to your health, and we're here to share the strength training habits that slow aging, according to science.

The 2022 hormone therapy position statement of The North American Menopause Society
Abstract “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” (NAMS) updates “The 2017 Hormone Therapy Position Statement of The North American Menopause Society” and identifies future research needs. An Advisory Panel of clinicians and researchers expert in the field of women’s health and menopause was recruited by NAMS to review the 2017 Position Statement, evaluate new literature, assess the evidence, and reach consensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence. The Advisory Panel’s recommendations were reviewed and approved by the NAMS Board of Trustees. Hormone therapy remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture. The risks of hormone therapy differ depending on type, dose, duration of use, route of administration, timing of initiation, and whether a progestogen is used. Treatment should be individualized using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation of the benefits and risks of continuing therapy. For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome VMS and prevention of bone loss. For women who initiate hormone therapy more than 10 years from menopause onset or who are aged older than 60 years, the benefit-risk ratio appears less favorable because of the greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia. Longer durations of therapy should be for documented indications such as persistent VMS, with shared decision-making and periodic reevaluation. For bothersome genitourinary syndrome of menopause symptoms not relieved with over-the-counter therapies in women without indications for use of systemic hormone therapy, low-dose vaginal estrogen therapy or other therapies (eg, vaginal dehydroepiandrosterone or oral ospemifene) are recommended.
Critical Role of Estrogens on Bone Homeostasis in Both Male and Female: From Physiology to Medical Implications
Bone is a multi-skilled tissue, protecting major organs, regulating calcium phosphate balance and producing hormones. Its development during childhood determines height and stature as well as resistance against fracture in advanced age. Estrogens are key regulators of bone turnover in both females and males. These hormones play a major role in longitudinal and width growth throughout puberty as well as in the regulation of bone turnover. In women, estrogen deficiency is one of the major causes of postmenopausal osteoporosis. In this review, we will summarize the main clinical and experimental studies reporting the effects of estrogens not only in females but also in males, during different life stages. Effects of estrogens on bone involve either Estrogen Receptor (ER)α or ERβ depending on the type of bone (femur, vertebrae, tibia, mandible), the compartment (trabecular or cortical), cell types involved (osteoclasts, osteoblasts and osteocytes) and sex. Finally, we will discuss new ongoing strategies to increase the benefit/risk ratio of the hormonal treatment of menopause.

Study Reveals How Much Exercise Older Adults Need Each Week To Live Longer
New research suggests that this level of physical activity can help you extend your lifespan, improve your cognition and more.

Massive biomolecular shifts occur in our 40s and 60s, Stanford Medicine researchers find
Time marches on predictably, but biological aging is anything but constant, according to a new Stanford Medicine study.
